Heterozygote Advantage of the Type II Deiodinase Thr92Ala Polymorphism on Intrahospital Mortality of COVID-19
Authors:
- Daniele Carvalhal de Almeida BeltrãoDBDaniele Carvalhal de Almeida Beltrão
- Giulia CarvalhalGCGiulia Carvalhal
- Fabricia Elizabeth de Lima BeltrãoFBFabricia Elizabeth de Lima Beltrão
- Jair de Souza Braga FilhoJFJair de Souza Braga Filho
- Jocyel de Brito OliveiraJOJocyel de Brito Oliveira
- Joice dos Santos de JesusJJJoice dos Santos de Jesus
- Gabriel Jeferson Rodríguez MachadoGMGabriel Jeferson Rodríguez Machado
- Hatilla dos Santos SilvaHSHatilla dos Santos Silva
- Helena Mariana Pitangueira TeixeiraHTHelena Mariana Pitangueira Teixeira
- Juliana Lopes RodriguesJRJuliana Lopes Rodrigues
- Camila Alexandrina Viana de FigueiredoCFCamila Alexandrina Viana de Figueiredo
- Ryan dos Santos CostaRCRyan dos Santos Costa
Open Access
- 9 February 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (6) , e2488-e2501
Abstract
Context: The type 2 deiodinase and its Thr92Ala-DIO2 polymorphism have been linked to clinical outcomes in acute lung injury and pulmonary fibrosis. Objective: Our objectives were to evaluate were cumulative mortality during admission according to Thr92Ala-DIO2 polymorphism. Methods: Here we conducted an observational, longitudinal, and prospective cohort study to investigate a possible association between the Thr92Ala-DIO2 polymorphism and intrahospital mortality from COVID-19 in adult patients admitted between June and August 2020. Blood biochemistry, thyroid function tests, length of stay, comorbidities, complications, and severity scores were also studied according to Thr92Ala-DIO2 polymorphism. Results: In total, 220 consecutive patients (median age 62; 48-74 years) were stratified into 3 subgroups: Thr/Thr (n = 79), Thr/Ala (n = 119), and Ala/Ala (n = 23). While the overall mortality was 17.3%, the lethality was lower in Ala/Thr patients (12.6%) than in Thr/Thr patients (21.7%) or Ala/Ala patients (23%). The heterozygous genotype (Thr/Ala) was associated with a 47% reduced risk of intrahospital mortality whereas univariate and multivariate logistic regression adjusted for multiple covariates revealed a reduction that ranged from 51% to 66%. The association of the Thr/Ala genotype with better clinical outcomes was confirmed in a metanalysis of 5 studies, including the present one. Conclusion: Here we provide evidence for a protective role played by Thr92Ala-DIO2 heterozygosity in patients with COVID-19. This protective effect follows an inheritance model known as overdominance, in which the phenotype of the heterozygote lies outside the phenotypical range of both homozygous.Keywords
This publication has 67 references indexed in Scilit:
- Inhibition of endoplasmic reticulum stress alleviates lipopolysaccharide-induced lung inflammation through modulation of NF-κB/HIF-1α signaling pathwayScientific Reports, 2013
- Association Analyses of Variants in the DIO2 Gene with Early-Onset Type 2 Diabetes Mellitus in Pima IndiansThyroid®, 2012
- Type 2 Deiodinase and Host Responses of Sepsis and Acute Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Impact of thyroid function and polymorphisms in the type 2 deiodinase on blood pressure: the Rotterdam Study and the Rotterdam Scan StudyClinical Endocrinology, 2009
- Triiodo- l -thyronine Rapidly Stimulates Alveolar Fluid Clearance in Normal and Hyperoxia-injured LungsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Low triiodothyronine: a strong predictor of outcome in acute stroke patientsEuropean Journal of Clinical Investigation, 2007
- Ala92 Type 2 Deiodinase Allele Increases Risk for the Development of HypertensionHypertension, 2007
- Deiodinases: implications of the local control of thyroid hormone actionJournal of Clinical Investigation, 2006
- Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of ChinaJournal of Medical Genetics, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003